000078.SZ
Shenzhen Neptunus Bioengineering Co., Ltd. [000078.SZ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
000078.SZ Stock Summary
Top 10 Correlated ETFs
000078.SZ
Top 10 Correlated Stocks
000078.SZ
In the News
000078.SZ Financial details
Company Rating
Strong Buy
Market Cap
8.39B
Income
-1.05B
Revenue
39.67B
Book val./share
1.73
Cash/share
1.29
Dividend
-
Dividend %
-
Employees
9.87K
Optionable
No
Shortable
Yes
Earnings
28 Apr 2022
P/E
-8.54
Forward P/E
-
PEG
0.17
P/S
0.22
P/B
1.76
P/C
2.36
P/FCF
-7.76
Quick Ratio
0.91
Current Ratio
1.06
Debt / Equity
2.64
LT Debt / Equity
0.07
-
-
EPS (TTM)
-0.4
EPS next Y
-
EPS next Q
-
EPS this Y
-487.36%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-0.29%
Revenue Q/Q
0.38%
EPS Q/Q
-88.03%
-
-
-
-
SMA20
0.33%
SMA50
-2.24%
SMA100
-9.5%
Inst Own
-
Inst Trans
-
ROA
-3%
ROE
-18%
ROC
-0.12%
Gross Margin
10%
Oper. Margin
-2%
Profit Margin
-3%
Payout
-73%
Shs Outstand
2.75B
Shs Float
1.5B
-
-
-
-
Target Price
-
52W Range
2.97-3.83
52W High
+1.67%
52W Low
+52.5%
RSI
46.85
Rel Volume
0.62
Avg Volume
12.34M
Volume
7.63M
Perf Week
-0.65%
Perf Month
-6.15%
Perf Quarter
-9.23%
Perf Half Y
-9.5%
-
-
-
-
Beta
0.51828
-
-
Volatility
0.01%, 0.03%
Prev Close
-0.33%
Price
3.05
Change
0%
000078.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 14.51 | 15.68 | 15.26 | 15.62 | 14.38 | |
| Net income per share | 0.17 | 0.19 | -0.02 | 0.1 | -0.38 | |
| Operating cash flow per share | -0.43 | 0.86 | 0.63 | 0.33 | -0.02 | |
| Free cash flow per share | -0.51 | 0.79 | 0.57 | 0.28 | -0.06 | |
| Cash per share | 1.4 | 2.31 | 2.14 | 1.58 | 1.26 | |
| Book value per share | 2.26 | 2.36 | 2.24 | 2.22 | 1.78 | |
| Tangible book value per share | 1.09 | 1.56 | 1.76 | 1.69 | 1.46 | |
| Share holders equity per share | 2.26 | 2.36 | 2.24 | 2.22 | 1.78 | |
| Interest debt per share | 5.29 | 5.37 | 5.82 | 5.12 | 4.92 | |
| Market cap | 7.88B | 9.87B | 10.52B | 9.28B | 8.73B | |
| Enterprise value | 16.86B | 16.78B | 19.46B | 17.73B | 17.65B | |
| P/E ratio | 17.59 | 19.17 | -254.75 | 35.98 | -8.8 | |
| Price to sales ratio | 0.21 | 0.24 | 0.26 | 0.23 | 0.23 | |
| POCF ratio | -6.95 | 4.35 | 6.37 | 10.71 | -135.78 | |
| PFCF ratio | -5.85 | 4.7 | 7 | 12.59 | -55.06 | |
| P/B Ratio | 1.32 | 1.58 | 1.79 | 1.59 | 1.86 | |
| PTB ratio | 1.32 | 1.58 | 1.79 | 1.59 | 1.86 | |
| EV to sales | 0.44 | 0.4 | 0.49 | 0.43 | 0.47 | |
| Enterprise value over EBITDA | 6.9 | 6.2 | 9.22 | 8.87 | 14.37 | |
| EV to operating cash flow | -14.86 | 7.39 | 11.79 | 20.47 | -274.36 | |
| EV to free cash flow | -12.5 | 7.98 | 12.94 | 24.05 | -111.25 | |
| Earnings yield | 0.06 | 0.05 | 0 | 0.03 | -0.11 | |
| Free cash flow yield | -0.17 | 0.21 | 0.14 | 0.08 | -0.02 | |
| Debt to equity | 2.18 | 2.08 | 2.43 | 2.16 | 2.56 | |
| Debt to assets | 0.32 | 0.32 | 0.36 | 0.33 | 0.33 | |
| Net debt to EBITDA | 3.67 | 2.55 | 4.24 | 4.23 | 7.26 | |
| Current ratio | 1.1 | 1.09 | 1.06 | 1.06 | 1.06 | |
| Interest coverage | 1.12 | 2.1 | 2 | 1.97 | 1.02 | |
| Income quality | -1.64 | 4.1 | -39.98 | 3.36 | 0.06 | |
| Dividend Yield | 0.15 | 0.14 | 0.07 | 0.06 | 0.07 | |
| Payout ratio | 2.59 | 2.6 | -18.69 | 2.19 | -0.65 | |
| Sales general and administrative to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.1 | 0.09 | 0.07 | 0.08 | 0.06 | |
| Capex to operating cash flow | 0.19 | -0.07 | -0.09 | -0.15 | 1.47 | |
| Capex to revenue | -0.01 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -1.63 | -1.11 | -0.76 | -0.48 | -0.34 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 2.94 | 3.22 | 0.89 | 2.21 | 3.89 | |
| ROIC | 0.04 | 0.08 | -0.01 | 0.04 | 0.07 | |
| Return on tangible assets | 0.01 | 0.01 | 0 | 0.01 | -0.03 | |
| Graham Net | -3.7 | -2.64 | -2.58 | -2.54 | -2.72 | |
| Working capital | 3.06B | 2.74B | 1.76B | 1.85B | 1.83B | |
| Tangible asset value | 2.9B | 4.12B | 4.62B | 4.45B | 3.85B | |
| Net current asset value | -363.9M | 1.25B | 1.4B | 1.32B | 1.38B | |
| Invested capital | 2.18 | 2.08 | 2.43 | 2.16 | 2.56 | |
| Average receivables | 21.49B | 24.58B | 24.18B | 23.65B | 23.43B | |
| Average payables | 10.1B | 11.42B | 11.38B | 10.39B | 10.06B | |
| Average inventory | 3.64B | 3.84B | 3.81B | 3.85B | 3.99B | |
| Days sales outstanding | 234.59 | 215.41 | 217.71 | 208.26 | 226.01 | |
| Days payables outstanding | 118.26 | 122.05 | 110.69 | 100.13 | 107.85 | |
| Days of inventory on hand | 43.25 | 37.78 | 40.3 | 37.77 | 44.95 | |
| Receivables turnover | 1.56 | 1.69 | 1.68 | 1.75 | 1.61 | |
| Payables turnover | 3.09 | 2.99 | 3.3 | 3.65 | 3.38 | |
| Inventory turnover | 8.44 | 9.66 | 9.06 | 9.66 | 8.12 | |
| ROE | 0.07 | 0.08 | -0.01 | 0.04 | -0.21 | |
| Capex per share | -0.08 | -0.06 | -0.06 | -0.05 | -0.04 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 3.49 | 3.38 | 4.11 | 3.37 | 3.62 | |
| Net income per share | 0.04 | 0.03 | 0.01 | -0.46 | 0.04 | |
| Operating cash flow per share | 0 | 0.03 | 0.01 | -0.46 | 0.04 | |
| Free cash flow per share | -0.01 | 0.02 | 0.01 | -0.47 | 0.03 | |
| Cash per share | 1.43 | 1.39 | 1.22 | 1.26 | 1.29 | |
| Book value per share | 2.23 | 2.25 | 2.25 | 1.78 | 1.73 | |
| Tangible book value per share | 1.72 | 1.72 | 1.73 | 1.46 | 1.42 | |
| Share holders equity per share | 2.23 | 2.25 | 2.25 | 1.78 | 1.73 | |
| Interest debt per share | 4.6 | 4.47 | 4.5 | 4.73 | 4.65 | |
| Market cap | 10.15B | 9.6B | 8.52B | 8.73B | 9.32B | |
| Enterprise value | 18.28B | 17.73B | 17.13B | 17.65B | 18.54B | |
| P/E ratio | 25.2 | 30.21 | 56.03 | -1.8 | 21.14 | |
| Price to sales ratio | 1.1 | 1.08 | 0.79 | 0.98 | 0.94 | |
| POCF ratio | 0 | 120.82 | 224.1 | -7.22 | 84.56 | |
| PFCF ratio | -411.61 | 150 | 514.76 | -7.03 | 115.1 | |
| P/B Ratio | 1.72 | 1.62 | 1.43 | 1.86 | 1.96 | |
| PTB ratio | 1.72 | 1.62 | 1.43 | 1.86 | 1.96 | |
| EV to sales | 1.99 | 1.99 | 1.58 | 1.99 | 1.86 | |
| Enterprise value over EBITDA | 46.48 | 72.85 | 74.42 | 206.84 | 46.04 | |
| EV to operating cash flow | 0 | 223.26 | 450.83 | -14.58 | 168.12 | |
| EV to free cash flow | -741.31 | 277.17 | 1.04K | -14.2 | 228.83 | |
| Earnings yield | 0.01 | 0.01 | 0 | -0.14 | 0.01 | |
| Free cash flow yield | 0 | 0.01 | 0 | -0.14 | 0.01 | |
| Debt to equity | 2.01 | 1.97 | 1.97 | 2.56 | 2.64 | |
| Debt to assets | 0.32 | 0.32 | 0.32 | 0.33 | 0.34 | |
| Net debt to EBITDA | 20.67 | 33.42 | 37.42 | 104.47 | 22.88 | |
| Current ratio | 1.07 | 1.07 | 1.07 | 1.06 | 1.06 | |
| Interest coverage | 0.54 | 1.03 | 0.87 | -2.88 | 0.72 | |
| Income quality | 0 | 1 | 1 | 1 | 1 | |
| Dividend Yield | 0.01 | 0.02 | 0 | 0.05 | 0.01 | |
| Payout ratio | 0.78 | 2.59 | 0.78 | -0.33 | 0.79 | |
| Sales general and administrative to revenue | 0.03 | 0 | 0.05 | -0.06 | 0.03 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.08 | 0.08 | 0.08 | 0.06 | 0.06 | |
| Capex to operating cash flow | 0 | -0.19 | -0.56 | 0.03 | -0.27 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.39 | 1.23 | 0.85 | 4.3 | 1.25 | |
| ROIC | 0.01 | 0 | 0 | -0.07 | 0.01 | |
| Return on tangible assets | 0 | 0 | 0 | -0.04 | 0 | |
| Graham Net | -2.43 | -2.42 | -2.5 | -2.72 | -2.56 | |
| Working capital | 1.96B | 2.13B | 2.1B | 1.83B | 1.89B | |
| Tangible asset value | 4.53B | 4.54B | 4.55B | 3.85B | 3.91B | |
| Net current asset value | 1.41B | 1.53B | 1.53B | 1.38B | 1.49B | |
| Invested capital | 2.01 | 1.97 | 1.97 | 2.56 | 2.64 | |
| Average receivables | 23.45B | 23.41B | 23.48B | 23.52B | 23.68B | |
| Average payables | 10.04B | 10B | 10.08B | 10.12B | 10.13B | |
| Average inventory | 3.66B | 3.44B | 3.5B | 3.92B | 4.13B | |
| Days sales outstanding | 229.63 | 235.47 | 196.18 | 237.46 | 216.38 | |
| Days payables outstanding | 110.96 | 112.77 | 92.65 | 112.37 | 103.18 | |
| Days of inventory on hand | 38.97 | 38.05 | 33.15 | 46.84 | 41.08 | |
| Receivables turnover | 0.39 | 0.38 | 0.46 | 0.38 | 0.42 | |
| Payables turnover | 0.81 | 0.8 | 0.97 | 0.8 | 0.87 | |
| Inventory turnover | 2.31 | 2.37 | 2.71 | 1.92 | 2.19 | |
| ROE | 0.02 | 0.01 | 0.01 | -0.26 | 0.02 | |
| Capex per share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
000078.SZ Frequently Asked Questions
What is Shenzhen Neptunus Bioengineering Co., Ltd. stock symbol ?
Shenzhen Neptunus Bioengineering Co., Ltd. is a CN stock and trading under the symbol 000078.SZ
What is Shenzhen Neptunus Bioengineering Co., Ltd. stock quote today ?
Shenzhen Neptunus Bioengineering Co., Ltd. stock price is $3.05 today.
Is Shenzhen Neptunus Bioengineering Co., Ltd. stock public?
Yes, Shenzhen Neptunus Bioengineering Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 12.34M
- Market Capitalization 8.39B
- Employee 9.87K
- CEO Mr. Feng Zhang
- Headquarters Shenzhen,CN
- IPO Date 1998-12-18
-
Website
https://www.neptunus.com 
Shenzhen Neptunus Bioengineering Co., Ltd. researches and develops, manufactures, and sells pharmaceutical products primarily in China. It offers drugs in the fields of anti-tumor, cardio-cerebrovascular, marine drugs, and other fields. The company was founded in 1989 and is based in Shenzhen, China.
